Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Research article

Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer

Authors: Marjo Pylväs-Eerola, Peeter Karihtala, Ulla Puistola

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Oxidative stress is a widely seen phenomenon in several carcinomas. Increasing evidence also suggests that it has a significant role in the development of epithelial ovarian carcinoma (EOC). 8-Hydroxydeoxyguanosine (8-OHdG) is one of the main indicators of oxidative stress and increased expression of 8-OHdG has previously been seen in EOC. DJ-1 is an oncoprotein connected to oxidative stress regulation, but its role in ovarian cancer is not well known. We investigated redox status in different histotypes of EOC by measuring serum 8-OHdG and DJ-1 concentrations and their associations with known prognostic factors.

Methods

Serum samples from newly diagnosed EOC patients were collected in 1996–2009 and stored at the Department of Obstetrics and Gynecology, Oulu University Hospital. Serum 8-OHdG and DJ-1 levels were measured by using commercially available ELISA kits. Clinical data was gathered retrospectively from the patients` files. Results were analyzed by using SPSS software.

Results

In total, 112 patient samples were analyzed (38 serous, 20 mucinous, 34 endometrioid and 20 clear-cell). High serum 8-OHdG levels were associated with poor overall survival (OS) (p = 0.019), poor disease-free survival (DFS) (p = 0.020), platinum resistance (p = 0.002), serous histology versus other (p = 0.033), stage III–IV versus I–II (p = 0.009) and suboptimal surgical outcome (p = 0.012). Regarding histotypes, in the endometrioid EOC group in particular, serum 8-OHdG levels were significantly associated with poor DFS (p = 0.005), suboptimal surgical outcome (p = 0.025), and platinum resistance (p = 0.007). The prognostic significance of 8-OHdG in patients with endometrioid cancer in terms of DFS was confirmed in Cox regression analysis. High DJ-1 levels were associated with high histological grade (p = 0.029) and nonsignificantly associated with serous histology vs. other histology (p = 0.089).

Conclusions

An elevated serum 8-OHdG level is a significant predictor of poor prognosis, especially in cases of the endometrioid subtype of ovarian carcinoma. High 8-OHdG levels are associated with all traditional factors of poor prognosis in ovarian cancer and they also predict earlier development of platinum resistance. These results could be valuable when deciding the primary treatment mode for EOC patients.

Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med. 2004;229:546–52.

Murdoch WJ. Carcinogenic potential of ovulatory genotoxity. Biol Reprod. 2005;73:586–90.CrossRefPubMed

Murdoch WJ, Van Kirk EA, Alexander BM. Damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med. 2005;230:429–33.

Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–67.CrossRefPubMed

Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, et al. Ovulation and extra-ovarian origin of ovarian cancer. Sci Rep. 2014; doi:10.1038/srep06116.

Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.CrossRefPubMed

Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer. 2009;19:1047–51.CrossRefPubMed

Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer. 2010;102:1018–23.CrossRefPubMedPubMedCentral

Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, et al. Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br J Cancer. 2009;100:381–8.CrossRefPubMed

10.

Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear 8-hydroxy-2`-deoxyguanosine, a survival biomarker in patients with cutaneous melanoma. Oncol Rep. 2010;23:329–35.PubMed

11.

Shen J, Deiniger P, Hunt JD, Zhao H. 8-Hydroxy-2`-deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with non-small-cell lung cancer. Cancer. 2007;109:574–80.CrossRefPubMed

12.

Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B- cell lymphoma. Exp Hematol Oncol. 2012; doi:10.1186/2161-3619-1-2.

13.

He H, Zhao Y, Wang N, Zhang L, Wang C. 8-Hydroxy-2`-deoxyguanosine expression predicts outcome of esophageal cancer. Ann Diagn Pathol. 2014;18:326–38.CrossRefPubMed

14.

Kondo S, Toyokuni S, Iwasa Y. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med. 1999;27:401–10.CrossRefPubMed

15.

Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 2008;259:218–30.CrossRefPubMed

16.

Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A. 2005;102:9691–6.CrossRefPubMedPubMedCentral

17.

Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263–73.CrossRefPubMed

18.

Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, et al. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24:159–60.CrossRefPubMed

19.

Merikallio H, Pääkkö P, Kinnula VL, Harju T, Soini Y. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 2012;43:577–84.CrossRefPubMed

20.

Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001;7:3328–35.PubMed

21.

Zhu XL, Wang ZF, Lei WB, Zhuang HW, Jiang HY, Wen WP. DJ-1: a novel independent prognostic marker for survival in glottic squamous cell carcinoma. Cancer Sci. 2010;101:1320–5.CrossRefPubMed

22.

Yuen HF, Chan YP, Law S, Srivastava G, El-Tanani M, Mak TW, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3593–602.CrossRefPubMed

23.

Chen LL, Tian JJ, Su L, Jing Y, Zhang SC, Zhang HX, et al. DJ-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol. 2015;141:315–21.CrossRefPubMed

24.

Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsiais G, Tsompanidou C, Simopoulos C, et al. B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Pancreatology. 2013;13:564–9.CrossRefPubMed

25.

Morelli M, Scumaci D, Di Cello A, Venturella R, Donato G, Faniello MC, et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Int J Gynecol Cancer. 2014;24:649–58.CrossRefPubMed

26.

Pylväs M, Puistola U, Laatio L, Kauppila S, Karihtala P. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Anticancer Res. 2011;21:1411–5.

27.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed

28.

Hirano T. Repair system of 7, 8-dihydro-8-oxoguanine as a defense line against carcinogenesis. J Radiat Res. 2008;49:329–40.CrossRefPubMed

29.

Cooke MS, Evans MD, Dove R, Rozalski R, Gackowski D, Siomek A, et al. DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res. 2005;574:58–66.CrossRefPubMed

30.

Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X, et al. The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res. 2013;doi:10.1186/1757-2215-6-74.

31.

Valavanidis A, Viachogianni T, Fiotakis C. 8-Hydroxy-2-deoxyguanisine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Exotoxicol Rev. 2009;27:120–39.CrossRef

32.

Pylväs M, Puistola U, Kauppila S, Karihtala P. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer. 2010;46:1661–7.CrossRefPubMed

33.

Sova H, Kangas J, Puistola U, Santala M, Liakka A, Karihtala P. Down-regulation of 8-hydroxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer. Anticancer Res. 2012;32:3037–44.PubMed

34.

Hayden A, Douglas J, Sommerland M, Andrews L, Gould K, Hussain S, et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol. 2014;32:806–14.CrossRefPubMed

35.

Gu L, Cui T, Fan C, Zhao H, Zhao C, Lu L, et al. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem Biophys Res Commun. 2009;383:469–74.CrossRefPubMed

36.

Ismail IA, Kang HS, Lee HJ, Kwon BM, Hong SH. 2'-Benzoyloxycinnamaldehyde-mediated DJ-1 upregulation protects MCF-7 cells from mitochondrial damage. Biol Pharm Bull. 2012;35:895–902.CrossRefPubMed

37.

Inberg A, Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. J Biol Chem. 2010;285:25686–98.CrossRefPubMedPubMedCentral

38.

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol. 2008;39:87–95.CrossRefPubMed

39.

Zhu ZM, Li ZR, Huang Y, Yu HH, Huang XS, Shao JH, et al. DJ-1 is involved in the peritoneal metastasis of gastric cancer through activation of the Akt signaling pathway. Oncol Rep. 2014;31:1489–97.PubMed

40.

Kawate T, Iwaya K, Kikuchi R, Kaise H, Oda M, Sato E, et al. DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2013;139:51–9.CrossRefPubMed

41.

Osman WM, Abd El Atti RM, Abou Gabal HH. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: a possible role in carcinogenesis. J Egypt Natl Canc Inst. 2013;25:223–30.CrossRefPubMed

42.

Bai J, Guo C, Sun W, Li M, Meng X, Yu Y, et al. DJ-1 may contribute to metastasis of non-small cell lung cancer. Mol Biol Rep. 2012;39:2697–703.CrossRefPubMed

43.

Karihtala P, Mäenpää J, Turpeenniemi-Hujanen T, Puistola U. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res. 2010;30:1001–6.PubMed

Title: Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer
Authors: Marjo Pylväs-Eerola
Peeter Karihtala
Ulla Puistola
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1504-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

What does satisfaction with wait times mean to cancer patients?

Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT

Enormous, rapidly growing breast mass

High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma

The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) – Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer